Márcia A. Inda

Philips (Finland) — Finland

Biochemistry, Genetics and Molecular Biology · Life Sciences

13h-index500citations57works0.02yr avg
OpenAlex↗ORCID↗Google Scholar↗Lab page↗

Accepting Students?

No reports yet. Know if this professor is taking students?

Research Topics

Bioinformatics and Genomic Networks(19), Estrogen and related hormone effects(17), Gene expression and cancer classification(9), Computational Drug Discovery Methods(8), Breast Cancer Treatment Studies(6)

Publications57 total

Supplemental Methods, supplemental tables 1 to 7, and supplemental figures 1 to 9 from Estrogen Receptor Pathway Activity Score to Predict Clinical Response or Resistance to Neoadjuvant Endocrine Therapy in Primary Breast Cancer
2023Open Access
Data from Estrogen Receptor Pathway Activity Score to Predict Clinical Response or Resistance to Neoadjuvant Endocrine Therapy in Primary Breast Cancer
2023Open Access
Supplemental Methods, supplemental tables 1 to 7, and supplemental figures 1 to 9 from Estrogen Receptor Pathway Activity Score to Predict Clinical Response or Resistance to Neoadjuvant Endocrine Therapy in Primary Breast Cancer
2023Open Access
Data from Estrogen Receptor Pathway Activity Score to Predict Clinical Response or Resistance to Neoadjuvant Endocrine Therapy in Primary Breast Cancer
2023Open Access
Supplementary Figure 1 from Selection of Personalized Patient Therapy through the Use of Knowledge-Based Computational Models That Identify Tumor-Driving Signal Transduction Pathways
2023Open Access
Supplementary Tables 1 - 5 from Selection of Personalized Patient Therapy through the Use of Knowledge-Based Computational Models That Identify Tumor-Driving Signal Transduction Pathways
2023Open Access
Supplementary Tables 1 - 5 from Selection of Personalized Patient Therapy through the Use of Knowledge-Based Computational Models That Identify Tumor-Driving Signal Transduction Pathways
2023Open Access
Data from Selection of Personalized Patient Therapy through the Use of Knowledge-Based Computational Models That Identify Tumor-Driving Signal Transduction Pathways
2023Open Access
Supplementary Methods from Selection of Personalized Patient Therapy through the Use of Knowledge-Based Computational Models That Identify Tumor-Driving Signal Transduction Pathways
2023Open Access
Data from Selection of Personalized Patient Therapy through the Use of Knowledge-Based Computational Models That Identify Tumor-Driving Signal Transduction Pathways
2023Open Access
Supplementary Methods from Selection of Personalized Patient Therapy through the Use of Knowledge-Based Computational Models That Identify Tumor-Driving Signal Transduction Pathways
2023Open Access
Supplementary Figure 1 from Selection of Personalized Patient Therapy through the Use of Knowledge-Based Computational Models That Identify Tumor-Driving Signal Transduction Pathways
2023Open Access
Impact of hormonal biomarkers on response to hormonal therapy in advanced and recurrent endometrial cancer
American Journal of Obstetrics and Gynecology·2021· 21 citedOpen Access
Heterogeneity in Signaling Pathway Activity within Primary and between Primary and Metastatic Breast Cancer
Cancers·2021· 5 citedOpen Access
Development of a qPCR based ER signaling pathway activity test predictive for response to endocrine therapy in ER IHC positive breast cancer patients
European Journal of Cancer·2020
5P Hormonal biomarkers can improve prediction of response to hormonal therapy in advanced and recurrent endometrial cancer: Results of the PROMOTE-R study
Annals of Oncology·2020
Abstract 4261: Development of quantitative multi-platform tests for easy readout of AR, ER, PI3K and MAPK pathway activity to unravel pathophysiology across cancer and tissue types
Cancer Research·2020
Heterogeneity in signaling pathway activity within primary and between primary and metastatic breast cancer
2020Open Access
Oestrogen receptor pathway activity is associated with outcome in endometrial cancer
British Journal of Cancer·2020· 25 citedOpen Access
ER and PI3K Pathway Activity in Primary ER Positive Breast Cancer Is Associated with Progression-Free Survival of Metastatic Patients under First-Line Tamoxifen
Cancers·2020· 25 citedOpen Access
page 1 of 3Next →

Frequent Co-authors

Anja van de Stolpe(32), Wim Verhaegh(28), Henk van Ooijen(21), Anne van Brussel(15), John W.M. Martens(13), Paul van de Wiel(11), Marcel Smid(10), John A. Foekens(10), Pantelis Hatzis(9), Hans Clevers(9), Rogier Versteeg(8), Eveline den Biezen(7), Laurent Holtzer(6), Hans van Zon(6), Andrew H. Sims(5), Arran Turnbull(5), Judith R. Kroep(5), Eveline den Biezen(5), Peter J.K. Kuppen(4), Ayoub Charehbili(4)